🇺🇸 FDA
Patent

US 12215090

Agents and methods for treating dysproliferative diseases

granted A61PA61P35/00

Quick answer

US patent 12215090 (Agents and methods for treating dysproliferative diseases) held by Tri-Institutional Therapeutics Discovery Institute, Inc. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tri-Institutional Therapeutics Discovery Institute, Inc.
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61P, A61P35/00